


## IDO1-IN-21

<b>Cat. No.:</b>	HY-149227
<b>CAS No.:</b>	2892432-98-1
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>19</sub> F <sub>2</sub> N <sub>3</sub> O <sub>6</sub> S
<b>Molecular Weight:</b>	479.45
<b>Target:</b>	Indoleamine 2,3-Dioxygenase (IDO)
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	IDO1-IN-21 (compound 10m) is an IDO1 inhibitor (IC <sub>50</sub> = 0.64 μM). IDO1-IN-21 effectively inhibits tumor growth in mice <sup>[1]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	IDO1 0.64 μM (IC <sub>50</sub> )								
<b>In Vitro</b>	<p>IDO1-IN-21 (0-50 μM; 48 h) inhibits the viability of SW480 cells with an IC<sub>50</sub> value of 28.64 μM<sup>[1]</sup>.            IDO1-IN-21 (0-10 μM; 48 h) inhibits the IDO1 of HeLa cells with an IC<sub>50</sub> value of 1.04 μM<sup>[1]</sup>.            MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>SW480 cells</td> </tr> <tr> <td>Concentration:</td> <td>0-50 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Suppressed viability of SW480 cells (IC<sub>50</sub> = 28.64 μM).</td> </tr> </table>	Cell Line:	SW480 cells	Concentration:	0-50 μM	Incubation Time:	48 h	Result:	Suppressed viability of SW480 cells (IC <sub>50</sub> = 28.64 μM).
Cell Line:	SW480 cells								
Concentration:	0-50 μM								
Incubation Time:	48 h								
Result:	Suppressed viability of SW480 cells (IC <sub>50</sub> = 28.64 μM).								
<b>In Vivo</b>	<p>IDO1-IN-21 (50, 100 mg/kg; i.p.; every three day for 21 consecutive days) inhibits growth of tumor in CT26 tumor-bearing mice<sup>[1]</sup>.            MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>CT26 tumor-bearing mice<sup>[1]</sup>.</td> </tr> <tr> <td>Dosage:</td> <td>50, 100 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal administration; every three day for 21 consecutive days.</td> </tr> <tr> <td>Result:</td> <td>Led to significant suppression of tumor growth.</td> </tr> </table>	Animal Model:	CT26 tumor-bearing mice <sup>[1]</sup> .	Dosage:	50, 100 mg/kg	Administration:	Intraperitoneal administration; every three day for 21 consecutive days.	Result:	Led to significant suppression of tumor growth.
Animal Model:	CT26 tumor-bearing mice <sup>[1]</sup> .								
Dosage:	50, 100 mg/kg								
Administration:	Intraperitoneal administration; every three day for 21 consecutive days.								
Result:	Led to significant suppression of tumor growth.								

### REFERENCES

---

[1]. Wang K, et al. Discovery of novel sulfonamide chromone-oxime derivatives as potent indoleamine 2,3-dioxygenase 1 inhibitors. Eur J Med Chem. 2023 Jun 5;254:115349.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA